Detalhe da pesquisa
1.
Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial.
Lancet Infect Dis
; 22(1): 73-84, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34563277